TAM
JANX icon

Tucker Asset Management’s Janux Therapeutics JANX Stock Holding History

Tucker Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-250
Closed -$3.02K – 1232
2023
Q1 		$3.02K Buy
+250
New +$4.16K ﹤0.01% 815

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Tucker Asset Management's JANX Position: Q2 2023 in Review

Tucker Asset Management sold out of Janux Therapeutics (JANX) in Q2 2023, closing a stake of 250 shares — an estimated $3.02K sold.

Tucker Asset Management first reported a position in JANX in Q1 2023 and held it in 1 quarter. The position peaked at $3.02K in Q1 2023. 54 funds tracked by Wall St. Rank hold JANX as of Q2 2023.

  • Tucker Asset Management reported no remaining Janux Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Tucker Asset Management sold 250 Janux Therapeutics shares in Q2 2023, an estimated $3.02K.
  • Tucker Asset Management first reported a position in Janux Therapeutics in Q1 2023 and held it in 1 quarter.
  • Tucker Asset Management's Janux Therapeutics position peaked at $3.02K in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2023.

Based on Tucker Asset Management's 13F filing for Q2 2023, filed 8 Sep 2023.